Customized watchlists with full streaming quotes from leading exchanges, such as NASDAQ, NYSE, AMEX, OTC Markets Small-Cap, LSE and more.
Period:
Draw Mode:
| Volume | 258,184 |
|
|||||
| News | - | ||||||
| Day High | 17.37 | Low High |
|||||
| Day Low | 16.54 | ||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| ALX Oncology Holdings Inc | ALXO | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| -0.175 | -1.04% | 16.695 | 14:23:03 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 16.81 | 16.54 | 17.37 | 16.87 |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 3,582 | 258,184 | $ 16.98 | $ 4,382,764 | - | 3.9357 - 17.42 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 14:21:57 | 8 | $ 16.74 | USD |
ALX Oncology Holdings Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 835.53M | 50.15M | - | 0 | -160.81M | -3.21 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
ALX Oncology News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical ALXO Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 15.60 | 17.37 | 13.88 | 15.82 | 429,580 | 1.10 | 7.02% |
| 1 Month | 11.25 | 17.37 | 10.49 | 13.95 | 625,493 | 5.45 | 48.40% |
| 3 Months | 14.75 | 17.42 | 10.49 | 13.91 | 491,521 | 1.95 | 13.19% |
| 6 Months | 6.77 | 17.42 | 6.485 | 12.85 | 463,269 | 9.93 | 146.60% |
| 1 Year | 5.54 | 17.42 | 3.9357 | 9.50 | 594,207 | 11.16 | 201.35% |
| 3 Years | 64.16 | 81.19 | 3.9357 | 17.35 | 406,485 | -47.47 | -73.98% |
| 5 Years | 30.44 | 117.45 | 3.9357 | 22.58 | 362,808 | -13.75 | -45.15% |
ALX Oncology Description
| ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches. |
